HOXB13-to-IL17BR Expression Ratio Is Related With Tumor Aggressiveness and Response to Tamoxifen of Recurrent Breast Cancer: A Retrospective Study

This publication has 17 references indexed in Scilit:

• The HOXB13:IL17BR Expression Index Is a Prognostic Factor in Early-Stage Breast Cancer
  Journal of Clinical Oncology, 2006
• Concordance among Gene-Expression–Based Predictors for Breast Cancer
  New England Journal of Medicine, 2006
• Re: Limits of predictive models using microarray data for breast cancer clinical treatment outcome.
  JNCI Journal of the National Cancer Institute, 2005
• How ADAM-9 and ADAM-11 Differentially From Estrogen Receptor Predict Response to Tamoxifen Treatment in Patients with Recurrent Breast Cancer: a Retrospective Study
  Clinical Cancer Research, 2005
• Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome
  JNCI Journal of the National Cancer Institute, 2005
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
  The Lancet, 2005
• Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling
  Journal of Clinical Oncology, 2005
• Urokinase-Type Plasminogen Activator System in Breast Cancer
  Cancer Research, 2004
• A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen
  Published by Elsevier ,2004
• Assessment of response to therapy in advanced breast cancer.A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland
  Cancer, 1977